TAG:
lab test
Summary and Overview of Lab Industry
By Robert Michel | From the Volume VII No. 18 – December 25, 2000 Issue
If there is any common theme to the different chapters of this White Paper on the laboratory industry, it is probably this: in the next couple of years, clinical laboratories will continue to have one foot in the past and one foot in the future. Simply put, lab administrators will continue to manag…
Genetics Tidal Wave is Rapidly Approaching
By R. Lewis Dark | From the Volume VII No. 17 – December 4, 2000 Issue
EVERYONE IN THE CLINICAL LAB BUSINESS KNOWS that our business will soon be dominated by genetic and molecular testing technology. However, most lab administrators and pathologists believe that we are several years away from the widespread clinical use of such technology in laboratory testing. In pr…
Year’s Ten Biggest Stories Reveal Modest Changes
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
CEO SUMMARY: In many ways, 2000 was a relatively quiet year for laboratory organizations. This list of the ten biggest stories in the lab industry for 2000 demonstrates that the most innovative laboratory organizations in the United States are “raising the bar” for service and quality…
Ortho-Clinical Diagnostics Embraces New Testing Technology
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
CEO SUMMARY: Despite a decade of consolidation, competition among the world’s largest diagnostics manufacturers remains intense. In response to this competition, Ortho-Clinical Diagnostics (OCD) is preparing a variety of new products and services for its clinical laboratory customers. I…
Dynacare’s IPO is Funded, Specialty Labs’ IPO is Next
By Robert Michel | From the Volume VII No. 17 – December 4, 2000 Issue
IT WAS A DISAPPOINTING TRIP to the public equity markets for Dynacare, Inc. last month. The lab company raised only $50 million in its initial public offering (IPO). Dynacare had hoped to harvest as much as $89 million from this IPO. Plans were to sell seven million shares at about …
Prognostic versus Diagnostic Lab Medicine
By R. Lewis Dark | From the Volume VII No. 16 – November 13, 2000 Issue
MOST OF YOU ARE FAMILIAR WITH THE RACE TO DEVELOP effective laboratory tests and pharmaceuticals based on rapidly-developing genetic and molecular knowledge. We all ask the same question: when will my laboratory have to buy this technology and offer these new tests? For most of us, the answer is “…
Medical Arts Lab Opts To File For Chapter 11 Bankruptcy
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: Dissident shareholders and a crushing debt burden are the reason Medical Arts Laboratory decided to file for reorganization under Chapter 11 bankruptcy laws. Both factors are the legacy of an ill-fated attempt to create a national laboratory organization between 1994 and 1997…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
Cheerios® Teaching Consumers Facts About Laboratory Testing
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
FOR YEARS, BOTH HOSPITAL LABS and independent commercial labs considered physicians and payers to be the primary customers for lab testing. The lab testing needs of patients as customers seldom came up when lab managers discussed how to organize and deliver their lab’s testing services. In fact, m…
“November 13, 2000 Intelligence: Late Breaking Lab News”
By R. Lewis Dark | From the Volume VII No. 16 – November 13, 2000 Issue
Last Thursday was the day Dynacare, Inc. hoped to place its initial public offering. Dynacare seeks to raise as much as $89 million…
CURRENT ISSUE

Volume XXXII, No. 10 – July 14, 2025
This issue is strong on different flavors of enforcement that clinical laboratories, whether they want to or not, will need to contend with. Lab stakeholders provide insights that medical labs need to brace for more action to counter pending test reimbursement rate cuts under PAMA. Also, this issue provides the legal and regulatory landscape for clinical labs’ use of AI and how it evolves with the technology. AI is creating legal uncertainty for clinical labs, especially around data privacy and FDA oversight of AI tools in diagnostics.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized